Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Acetate1件: Acetate---43件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299
2ALX-0081----1件: 64
3Anfibatide1件: Anfibatide---1件: 64
4Anti-von Willebrand Factor Nanobody1件: Von Willebrand factor human---1件: 64
5Anti-von Willebrand Factor Nanobody, Caplacizumab2件: Caplacizumab,
Von Willebrand factor human		1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
6Anti-von Willebrand Factor Nanobody, INN = Caplacizumab2件: Caplacizumab,
Von Willebrand factor human		1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
7Apadamtase alfa1件: Apadamtase alfa---1件: 64
8Apademtase alfa----1件: 64
9ARC 1779----2件: 64, 288
10ARC1779----2件: 64, 288
11ARC1779 Injection----2件: 64, 288
12BAX930----1件: 64
13BAX930 - RECOMBINANT HUMAN ADAMTS13----1件: 64
14BAX930 or SHP655----1件: 64
15BORTEZOMIB1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
16Bortezomib Injection1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 64
17CABLIVI1件: Caplacizumab1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
18Cablivi®1件: Caplacizumab1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
19CAPLACIZUMAB1件: Caplacizumab1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
20Caplacizumab (ALX-0081)1件: Caplacizumab1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
21Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)2件: Caplacizumab,
Von Willebrand factor human		1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
22Caplacizumab (an anti-von Willebrand Factor Nanobody)2件: Caplacizumab,
Von Willebrand factor human		1件: D11160 1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64
23Corticosteroid treatment (Methylprednisolone or prednisolone)2件: Methylprednisolone,
Prednisolone		14件: D00407 ,
D00472 ,
D00751 ,
D00979 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 64
24Corticosteroids----10件: 41, 46, 49, 64, 97, 107, 164, 220, 296, 300
25Cryosupernatant plasma----1件: 64
26Cyclosporine1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬37件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302
27Danazol1件: Danazol1件: D00289 3件: AR,
ESR1,
PGR 💬		12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬5件: 60, 63, 64, 65, 285
28Desmopressin1件: Desmopressin2件: D00291 ,
D02235 		2件: AVPR2,
F8 💬		4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬5件: 6, 64, 72, 225, 288
29Desmopressin acetate2件: Acetate,
Desmopressin		2件: D00291 ,
D02235 		2件: AVPR2,
F8 💬		4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬2件: 64, 288
30Dexamethasone1件: Dexamethasone9件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
31HMED-IdeS1件: Imlifidase1件: D11470 --2件: 64, 221
32IDEC-C2B8, Ro 45-2294----1件: 64
33IdeS1件: Imlifidase1件: D11470 --2件: 64, 221
34IdeS (0.25 mg/kg)1件: Imlifidase1件: D11470 --1件: 64
35IdeS (0.50 mg/kg)1件: Imlifidase1件: D11470 --1件: 64
36Immunosuppressive treatment (eg, rituximab)1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 64
37MabThera1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271
38Magnesium1件: Magnesium---19件: 3, 6, 11, 13, 15, 46, 64, 70, 93, 97, 166, 225, 235, 256, 284, 291, 296, 297, 298
39MASP-2 antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬3件: 64, 66, 109
40Methylprednisolone1件: Methylprednisolone6件: D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬48件: 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
41Minirin1件: Desmopressin2件: D00291 ,
D02235 		2件: AVPR2,
F8 💬		4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬2件: 64, 288
42Octaplas1件: Plasma protein fraction (human)---1件: 64
43Octaplas infusion1件: Plasma protein fraction (human)---1件: 64
44Octaplas SD1件: Plasma protein fraction (human)---1件: 64
45OctaplasLG®----1件: 64
46Octaplas®LG1件: Plasma protein fraction (human)---1件: 64
47Octostim----2件: 64, 288
48OMS721----3件: 64, 66, 109
49OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬2件: 64, 109
50OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody1件: Narsoplimab1件: D11531 1件: MASP2 💬3件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬2件: 64, 109
51Other: standard of care----7件: 13, 49, 64, 85, 96, 245, 246
52Plasma exchange----5件: 13, 43, 44, 64, 222
53Plasma exchange (PE)----3件: 64, 66, 220
54Pooled Plasma (Human), Solvent/Detergent Treated----1件: 64
55PREDNISOLONE1件: Prednisolone8件: D00472 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
56Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬48件: 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
57RADAMTS-13----1件: 64
58Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13----1件: 64
59Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1----1件: 64
60Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs----1件: 64
61Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13----1件: 64
62Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13)----1件: 64
63Recombinant ADAMTS13----1件: 64
64Rituximab1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬49件: 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
65Romiplostim1件: Romiplostim1件: D08990 1件: MPL 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬4件: 60, 63, 64, 65
66SHP 655 (BAX 930)----1件: 64
67SHP655----1件: 64
68Standard of Care----10件: 6, 13, 46, 49, 51, 63, 64, 79, 171, 271
69Standard Plasma----1件: 64
70Standrd of Care treatment----1件: 64
71Sulfate1件: Sulfate ion---27件: 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 218, 222, 226, 265, 296, 297, 299
72Sulfate, Magnesium2件: Magnesium,
Sulfate ion		---1件: 64
73TAK-755----1件: 64
74TAK-755 or BAX930 or SHP655----1件: 64
75TAK-755 orBAX930 or SHP655----1件: 64
76Uniplas----1件: 64
77Von willebrand factor1件: Von Willebrand factor human---2件: 64, 288